Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The need to provide effective and timely antimicrobial treatment to cancer patients with infections is well recognized but tempered by preliminary, but accumulating, evidence that antibiotic-induced microbiome dysbiosis affects cancer therapy response, noninfectious toxicities, and infectious complications. Given only a minority of empirically treated cancer patients are proven to have a true bacterial infection, it is important to consider the potential negative consequences of extensive broad-spectrum antimicrobial use on the commensal microbiota. Herein, we review the literature substantiating the dilemma oncologists face when treating suspected or documented infections with respect to the interaction between the host microbiome, antibiotics, and cancer-related clinical outcomes. We propose microbiome-based explorations that could assist oncologists in optimizing treatment strategies for cancer-related infections as well as the cancer itself. In addition, we discuss knowledge gaps and challenges in this nascent field that must be addressed to deliver medically relevant, translational applications. We anticipate that the emerging knowledge regarding the role of the microbiota in the health of cancer patients may cause a reappraisal of the manner in which antibiotics are used in the oncologic setting and how microorganisms are viewed by oncologists. Clin Cancer Res; 23(13); 3263–8. ©2017 AACR. See related commentary by Fessler and Gajewski, p. 3229
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lagier, J.-C., Khelaifia, S., Alou, M. T., Ndongo, S., Dione, N., Hugon, P., Caputo, A., Cadoret, F., Traore, S. I., Seck, E. H., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.203 · Cited by 951
RetractedThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
The microbiome and innate immunity
Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016) · Nature · doi:10.1038/nature18847 · Cited by 2,012
Taur, Y., Xavier, J. B., Lipuma, L., Ubeda, C., Goldberg, J., Gobourne, A., Lee, Y. J., Dubin, K. A., Socci, N. D., Viale, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis580 · Cited by 1,020
Self-citationDubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“Finally, the abundance of the Bacteroidetes phylum was recently correlated with resistance to the development of immune-mediated colitis in melanoma patients treated with the immune check-point inhibitor, ipilimumab [31].”
BackgroundUbeda, C., Taur, Y., Jenq, R. R., Equinda, M. J., Son, T., Samstein, M., Viale, A., Socci, N. D., van den Brink, M. R. M., Kamboj, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43918 · Cited by 943
Self-citationTaur, Y., Jenq, R. R., Perales, M.-A., Littmann, E. R., Morjaria, S., Ling, L., No, D., Gobourne, A., Viale, A., Dahi, P. B., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554725 · Cited by 885 · cited 1×
“Similarly, the diversity of the gastrointestinal microbiome at the time of engraftment following HSCT is associated with risk of development of and mortality fromGVHD (20, 30).”
BackgroundSelf-citationFunctional characterization of the antibiotic resistance reservoir in the human microflora
Sommer, M. O. A., Dantas, G., & Church, G. M. (2009) · Science · doi:10.1126/science.1176950 · Cited by 878 · cited 1×
“As genomic methodologies advance in terms of decreasing price and rapid availability of results, the ability to usemicrobiome samples to rapidly determine the scope of pathogens and antibiotic resistance genes present within an individual is becoming a real possibility (36).”
BackgroundAntibiotics and the Gut Microbiota
Modi, S. R., Collins, J. J., & Relman, D. A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72333 · Cited by 667
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation
Jenq, R. R., Ubeda, C., Taur, Y., Menezes, C. C., Khanin, R., Dudakov, J. A., Liu, C., West, M. L., Singer, N. V., Equinda, M. J., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112408 · Cited by 626 · cited 2×
“For example, administration of antibiotics to mice undergoing hematopoietic stem cell transplantation (HSCT) significantly increased the severity of GHVD and mortality (19, 20).”
BackgroundSelf-citation
Cited by
Exploring the emerging role of the microbiome in cancer immunotherapy
Fessler, J., Matson, V., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0574-4 · Cited by 319
Tinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4006 · Cited by 161
Self-citationThe Microbiota: A New Variable Impacting Cancer Treatment Outcomes
Fessler, J. L., & Gajewski, T. F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0864 · Cited by 24
Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy
Nie, F., Guo, J., Pan, J., Guo, Z., Wang, C., Yan, J., & Ma, W. (2024) · Clinical and Translational Oncology · doi:10.1007/s12094-024-03615-0 · Cited by 4
“The potential of ATB abuse in patients with hematological malignancies to prevent infections also warrants consideration [24].”
Metadata
- Authors
- Galloway-Peña, J. R., Jenq, R. R., & Shelburne, S. A.
- Venue
- Clinical Cancer Research
- Published
- 2017-07-01
- Volume
- 23
- Issue
- 13
- Pages
- 3263-3268
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2602901677
- Cited by
- 32
- References
- 14
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient? https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-3173
- The paper
- Galloway-Peña, J. R., Jenq, R. R., & Shelburne, S. A. (2017). Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient? Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-3173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.